A new study adds to the evidence that metabolic factors play an important role in the pathogenesis of rheumatoid arthritis (RA). In this large, prospective cohort study, Liu et al. found that increased physical activity among women was associated with a reduced risk of RA…
Filgotinib Promising for RA
Research shows filgotinib may be safe and effective for treating rheumatoid arthritis. The drug’s manufacturer is expected to be submit a new drug application for filgotinib to the FDA in 2019…
FDA Approves AbbVie’s New Rheumatoid Arthritis Drug
(Reuters)—The U.S. Food and Drug Administration (FDA) on Friday approved AbbVie Inc.’s new treatment for rheumatoid arthritis (RA), a win for the drugmaker seeking to widen its portfolio as its blockbuster flagship therapy Humira (adalimumab) faces competition. The drug, Rinvoq (upadacitinib), is a JAK inhibitor. It is set to compete with Pfizer Inc.’s Xeljanz (tofacitinib)…
Otilimab Begins Phase 3 Clinical Studies for RA
In a four-part clinical trial program, researchers are assessing the safety and efficacy of otilimab with placebo in RA patients, along side conventional treatments, such as tofacitinib, and DMARDs…
ACR Prepares to Submit Rheumatoid Arthritis Alternative Payment Model
The ACR will soon submit the updated Rheumatoid Arthritis Alternative Payment Model to the Physician-Focused Payment Model Technical Advisory Committee for review and feedback.
Asthma, Allergic Disease, Passive Smoke Exposure & the Risk of RA
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases. One hypothesis is that inflammation in the respiratory tract results in autoantibody formation that later leads to disease. Kronzer et al. set out to narrow the knowledge gaps related to the oral-respiratory factors that may mediate RA pathogenesis.
Baricitinib: Early vs. Late Treatment Outcomes in RA Patients
Recent research found that RA patients who began treatment with baricitinib experienced greater improvement from baseline than patients who began treatment with methotrexate…
A More Complicated Pregnancy: Inflammatory Arthritis Increases the Risk for Adverse Outcomes
Pregnant women with inflammatory arthritis may have an increased risk for preterm delivery. New research examined the risk of preterm delivery and other pregnancy complications in women with RA and JIA vs. healthy controls…
RheumPAC Advocates for Department of Defense Arthritis Research Funding
The ACR’s nonpartisan political action committee is continuing to advocate for increased defense department funding for rheumatology research. Learn about RheumPAC’s efforts and how you can help.
RA Patients May Safely Stop Methotrexate in Tofacitinib Combination Therapy
RA patients who achieve low disease activity on tofacitinib and methotrexate combination therapy can safely cease methotrexate use, according to recent research…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 30
- Next Page »